Clinical Efficacy and Mechanism of Vitamin D2 in Treating Hashimoto's Thyroiditis
Lu Gan,Yuqi Li
DOI: https://doi.org/10.2147/jir.s441120
IF: 4.5
2024-02-22
Journal of Inflammation Research
Abstract:Lu Gan, Yuqi Li Department of Endocrinology, General Hospital of Ningxia Medical University, Yinchuan City, 750000, People's Republic of China Correspondence: Lu Gan, Ningxia Medical University General Hospital, 804 Shengli Street South Street, Yinchuan City, 750000, People's Republic of China, Tel +86-13709518674, Email Objective: Hashimoto's thyroiditis (HT) is one of the most common autoimmune diseases, with the highest incidence rate among autoimmune thyroid disorders. Vitamin D2 may have therapeutic effects on HT. This study aimed to elucidate the molecular mechanisms underlying vitamin D2 therapy for HT. Methods: Differentially expressed genes (DEGs) associated with vitamin D2-treated HT were identified, and the DEG-associated gene enrichment pathway was explored using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. The correlation between the hub genes and infiltrating immune cells was investigated, and the interactions among the hub genes and target drug and competing endogenous RNA (ceRNA; long non-coding RNA [lncRNA]–microRNA [miRNA]–messenger RNA [mRNA]) regulatory networks were determined. Results: GO and KEGG enrichment analyses identified a total of 102 DEGs (6 upregulated and 96 downregulated) in the vitamin D2-treated group samples. The area under the curve values of the identified 10 hub genes was as follows: CCR1(0.920), CXCL1 (0.960), CXCL8 (0.960), EGR1 (0.960), FCGR3B (0.920), FOS (1.000), FPR1 (0.840), MMP9 (0.720), PTGS2 (0.960), and TREM1 (1.000). The immune enrichment scores of the mast cell (P = 0.008), neutrophil (P = 0.016), and plasmacytoid dendritic cell (P = 0.016) were significantly decreased in the vitamin D2-treated group (P < 0.05). The hub gene/drug regulatory network included 8 hub genes, 108 molecular drugs, and 114 interaction relationship pairs. The ceRNA regulatory network included 129 lncRNAs, 145 miRNAs, mRNAs (hub genes), and 324 interaction relationship pairs. Conclusion: Vitamin D2 may play an immunomodulatory role by regulating the aforementioned immune-related molecules and immune cells, thereby improving its therapeutic effects on HT. Keywords: Hashimoto's thyroiditis, vitamin D2, RNA sequencing, differentially expressed genes, immune infiltration Hashimoto's thyroiditis (HT) is one of the most prevalent autoimmune diseases, with the highest incidence rate among autoimmune thyroid disorders. 1 Studies have revealed the annually increasing incidence of HT. In China, the prevalence of HT ranges from 0.2% to 1.3%. 2,3 HT pathology mainly includes diffuse lymphocyte and plasma cell infiltration, interstitial fibrosis, glandular atrophy, and acidic degeneration of follicles. 4 The onset of HT is indistinct; many patients are asymptomatic during the early stages, and the cardinal clinical feature is painless, diffuse goiter. Approximately half of the patients with HT develop hypothyroidism and require lifelong thyroid hormone replacement. The risk of papillary thyroid carcinoma in patients with HT is considerably higher than that in the general population. Furthermore, the presence of thyroid peroxidase antibody (TPOAb) and thyroglobulin antibody (TGAb) may lead to unexplained infertility, abortion, preterm delivery, and postpartum thyroid disorders. 5 Therefore, the high incidence of HT confers immense burdens on patients, the families of patients, and society. Vitamin D2 (ergocalciferol) from foods and vitamin D3 (cholecalciferol) from sunlight exposure collectively constitute vitamin D. 6 Vitamin D further undergoes biotransformation into more biologically active metabolites. In the liver, vitamin D is hydroxylated by 25-hydroxylase into its major circulating form, 25-hydroxyvitamin D (25OHD). Thus, blood 25OHD levels reflect vitamin D status from both diet and sunlight exposure. 7 Numerous studies have confirmed associations between HT and trace elements such as iodine and selenium; 8–11 however, the association between HT and vitamin D remains debatable. A recent review proposed that vitamin D deficiency may contribute to the pathophysiology, hypothyroidism, and autoimmunity of HT. 12 Moreover, a randomized controlled trial showed that vitamin D supplementation benefits HT remission; newly diagnosed patients with HT were randomly assigned to either an intervention group receiving weekly supplementation of 60,000 IU of vitamin D3 and 500 mg/day of calcium for 8 weeks or a control group receiving only 500 mg/day of calcium. The results of the trial showed that after 3 months, TPOAb decreased by 46.73% in the intervention group, which is significantly more than the 16.6% decrease in the control group (P = 0.028). 13 Additionally, Musco -Abstract Truncated-
immunology